In the clinical trial “Diabetes Prevention-Immune Tolerance” (DIAPREV-IT), the effect of administration of GAD conjugated to aluminum hydroxide (GAD-alum) was studied in normoglycemic children with anti-GAD antibodies and another type of positive antibody. Here, GAD1 is linked to diabetes mellitus.